Target intelligence / Profile preview

Adenosine receptor A1; Adenosine receptor A2A (A1AR; A2AAR)

Target
A1AR; A2AAR
Molecular classification
G protein-coupled receptor (GPCR), Purinergic receptor (P1), Cell surface receptor
01

Overview

Adenosine receptor A1 and A2A subtypes are integral membrane proteins in the G protein-coupled receptor family, activated by extracellular adenosine. A1 receptors are predominantly inhibitory, slowing metabolic activity in the brain and suppressing neurotransmitter release, with a key protective role in neurons and the heart. A2A receptors, in contrast, stimulate adenylate cyclase, increase cAMP, and have prominent anti-inflammatory and neuro-modulatory roles, especially in the brain and immune cells. Both subtypes are highly relevant in diverse diseases—cardiovascular, neurological, and oncological settings—and are targeted by numerous clinically used and investigational drugs.

Other names
Adenosine A1 receptorAdenosine A2A receptorA1ARA2AARP1 receptor subtypes A1 and A2A
02

Mechanism of action

Agonists bind and activate the receptor, triggering downstream G protein-mediated signaling, altering adenylate cyclase activity (A1 inhibits, A2A stimulates) Antagonists block receptor activation, modulating neurotransmission and cardiovascular function Selective modulation of neurotransmitter release, inflammatory pathways, or cardiac conduction

03

Biological functions

Signal transductionRegulation of neurotransmitter releaseCardiovascular modulation (heart rate, blood flow)Metabolic regulation in neural tissueModulation of immune responseProtecting neurons and cardiac tissue (A1)Anti-inflammatory effects (A2A)
04

Disease associations

Cardiovascular disease (e.g., arrhythmia, coronary disease)Neurodegenerative disorders (e.g., Parkinson’s disease)Sleep disordersCancerInflammatory diseases
05

Safety considerations

Cardiovascular effects: Bradycardia (A1 agonism); Tachycardia or arrhythmias (antagonism)CNS effects: Sedation (A1 agonism); Insomnia/anxiety (A2A antagonism or caffeine use)Risk of excessive anti-inflammatory effect or immunosuppression (A2A agonism)Drug interactions (e.g., with other stimulants or heart medications)
06

Interacting drugs

Caffeine (antagonist, non-selective)

4 more in the full profile.

07

Biomarkers

Altered receptor expression or signaling (potential Parkinson’s biomarker for A2A)Circulating adenosine levels in cardiovascular diseasePET tracers for imaging receptor density in neurodegenerative disease (research use)

Beyond the preview

Go deeper on Adenosine receptor A1; Adenosine receptor A2A (A1AR; A2AAR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adenosine receptor A1; Adenosine receptor A2A (A1AR; A2AAR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call